Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 4, 2012, Pages 445-454

  Han, Dan Dan ^a   Wang, Yun ^a   Zhang, Xin Hua ^a   Liu, Jin Rong ^a   Wang, Huai Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Fluoxetine; HIF 1 ; Monocrotaline; Pulmonary hypertension; ROS; Serotonin reuptake inhibitor; Serotonin transporter; VEGF

Indexed keywords

FLUOXETINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCROTALINE; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; HEART RIGHT VENTRICLE; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; UPREGULATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FLUOXETINE; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG; MALE; MAP KINASE SIGNALING SYSTEM; MONOCROTALINE; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859142970     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-011     Document Type: Article

References (41)

1. Adnot, S., and Eddahibi, S. 2003. Génétique et physiopathologie de l'hypertension artérielle pulmonaire primitive ou secondaire [Genetics and physiopathology of primary or secondary pulmonary artery hypertension]. Bull. Acad Natl. Med. 187(8): 1529-1542, discussion 1543-1545. PMID:15146583.
2. Anderson, J.R., and Nawarskas, J.J. 2010. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol. Rev. 18 (3): 148-162. doi:10.1097/CRD.0b013e3181d4e921. PMID:20395700.
3. Archer, S.L., Gomberg-Maitland, M., Maitland, M.L., Rich, S., Garcia, J.G.N., and Weir, E.K. 2008. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1a-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am. J. Physiol. Heart Circ. Physiol. 294(2): H570- H578. doi:10.1152/ajpheart.01324.2007. PMID:18083891.
4. BelAiba, R.S., Djordjevic, T., Bonello, S., Flügel, D., Hess, J., Kietzmann, T., and Görlach, A. 2004. Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions pulmonary artery smooth muscle cells. Biol. Chem. 385(3-4): 249-257.doi:10.1515/BC.2004.019. PMID:15134338.
5. Bianchi, P., Pimentel, D.R., Murphy, M.P., Colucci, W.S., and Parini, A. 2005. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB J. 19(6): 641-643. PMID:15703274.
6. Campbell, A.I.M., Zhao, Y., Sandhu, R., and Stewart, D.J. 2001. Cell-based gene transfer of vascular endothelial growth factorattenuates monocrotaline-induced pulmonary hypertension. Circulation, 104(18): 2242-2248. doi:10.1161/hc4201.097838.PMID:11684638.
7. Chan, S.Y., and Loscalzo, J. 2008. Pathogenic mechanisms of pulmonary arterial hypertension. J. Mol. Cell. Cardiol. 44(1): 14-30. doi:10.1016/j.yjmcc.2007.09.006. PMID:17950310.
8. Dorafshar, A.H., Angle, N., Bryer-Ash, M., Huang, D., Farooq, M.M., Gelabert, H.A., and Freischlag, J.A. 2003. Vascular endothelial growth factor inhibits mitogen-induced vascular smooth muscle cell proliferation. J. Surg. Res. 114(2): 179-186. doi:10.1016/S0022-4804(03)00254-3. PMID:14559444.
9. Eddahibi, S., and Adnot, S. 2006. Sérotonine et hypertension artérielle pulmonaire [Serotonin and pulmonary arterial hypertension].Rev. Mal. Respir. 23(Suppl. 2): 4S45-4S51.PMID:16733400.
10. Eddahibi, S., Hanoun, N., Lanfumey, L., Lesch, K.P., Raffestin, B., Hamon, M., and Adnot, S. 2000. Attenuated hypoxic pulmonaryhypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 105(11): 1555-1562. doi:10.1172/JCI8678.PMID:10841514.
11. Eddahibi, S., Humbert, M., Fadel, E., Raffestin, B., Darmon, M., Capron, F., et al. 2001. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108(8): 1141-1150. PMID:11602621.
12. Eddahibi, S., Morrell, N., d'Ortho, M.P., Naeije, R., and Adnot, S. 2002. Patho biology of pulmonary arterial hypertension. Eur.Respir. J. 20(6): 1559-1572. doi:10.1183/09031936.02.00081302.PMID:12503718.
13. Eddahibi, S., Chaouat, A., Morrell, N., Fadel, E., Fuhrman, C., Bugnet, A.S., et al. 2003. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation, 108(15): 1839-1844. doi:10.1161/01.CIR.0000091409.53101.E8. PMID:14530202.
14. Fu, D., Dai, A., Hu, R., Chen, Y., and Zhu, L. 2008. Expression and role of factor inhibiting hypoxia-inducible factor-1 in pulmonary arteries of rat with hypoxia-induced hypertension. Acta Biochim. Biophys. Sin. (Shanghai), 40(10): 883-892.PMID:18850054.
15. Guignabert, C., Izikki, M., Tu, L.I., Li, Z., Zadigue, P., Barlier-Mur, A.M., et al. 2006. Transgenic mice overexpressing the 5- hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ. Res. 98(10): 1323-1330. doi:10.1161/01.RES.0000222546.45372.a0. PMID:16614302.
16. Hassoun, P.M., Mouthon, L., Barbera, J.A., Eddahibi, S., Flores, S.C., Grimminger, F., et al. 2009. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54(Suppl. 1): S10-S19. doi:10.1016/j.jacc.2009.04.006. PMID:19555853.
17. Humbert, M., Morrell, N.W., Archer, S.L., Stenmark, K.R., MacLean, M.R., Lang, I.M., et al. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(Suppl. 12): 13S-24S. doi:10.1016/j.jacc.2004.02.029.PMID:15194174.
18. Lahm, T., Crisostomo, P.R., Markel, T.A., Wang, M., Lillemoe, K.D., and Meldrum, D.R. 2007. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Shock, 28(1): 4-14. doi:10.1097/shk.0b013e31804d1998. PMID:17510598.
19. Lai, Y.L., and Law, T.C. 2004. Chronic hypoxia- and monocrotalineinduced elevation of hypoxia-inducible factor-1 alpha levels and pulmonary hypertension. J. Biomed. Sci. 11(3): 315-321. PMID:15067214.
20. Lee, S.L., Wang, W.W., Finlay, G.A., and Fanburg, B.L. 1999. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am. J. Physiol. 277(2): L282-L291. PMID:10444522.
21. Lee, S.L., Simon, A.R., Wang, W.W., and Fanburg, B.L. 2001. H2O2 signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 281(3): L646-L652. PMID:11504692.
22. Lemus-Varela, M.L., Flores-Soto, M.E., Cervantes-Munguía, R., Torres-Mendoza, B.M.G., Gudiño-Cabrera, G., Chaparro-Huerta, V., et al. 2010. Expression of HIF-1a, VEGF and EPO in peripheral blood from patients with two cardiac abnormalities associated with hypoxia. Clin. Biochem. 43(3): 234-239. doi:10.1016/j.clinbiochem.2009.09.022. PMID:19804771.
23. Li, Q.F., and Dai, A.G. 2004. Hypoxia-inducible factor-1 alpha regulates the role of vascular endothelial growth factor on pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Chin. Med. J. (Engl.), 117(7): 1023-1028. PMID: 15265376.
24. Li, X.Q., Hong, Y., Wang, Y., Zhang, X.H., and Wang, H.L. 2006. Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin. Exp. Pharmacol. Physiol. 33(11): 1047-1051. doi:10.1111/j.1440-1681.2006.04485.x. PMID:17042913.
25. Li, D., Zhang, C., Song, F., Lubenec, I., Tian, Y., and Song, Q.H. 2009a. VEGF regulates FGF-2 and TGF-b1 expression in injuryendothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc. Res. 77(2): 134-142. doi:10.1016/j.mvr.2008.09.007. PMID:18948122.
26. Li, X., Zhang, X., Leathers, R., Makino, A., Huang, C., Parsa, P., et al. 2009b. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat. Med. 15(11): 1289-1297.doi:10.1038/nm.2021. PMID:19855400.
27. Liu, J.Q., and Folz, R.J. 2004. Extracellular superoxide enhances 5- HT-induced murine pulmonary artery vasoconstriction. Am. J. Physiol. Lung Cell. Mol. Physiol. 287(1): L111-L118. doi:10.1152/ajplung.00006.2004. PMID:15020294.
28. MacLean, M.R., and Dempsie, Y. 2009. Serotonin and pulmonary hypertension-frombench to bedside? Curr. Opin. Pharmacol. 9(3): 281-286. doi:10.1016/j.coph.2009.02.005. PMID:19286424.
29. MacLean, M.R., and Dempsie, Y. 2010. The serotonin hypothesis of pulmonary hypertension revisited. Adv. Exp. Med. Biol. 661: 309-322. doi:10.1007/978-1-60761-500-2_20. PMID:20204739.
30. MacLean, M.R., Herve, P., Eddahibi, S., and Adnot, S. 2000. 5- hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol. 131(2): 161-168. doi:10.1038/sj.bjp.0703570.PMID:10991906.
31. Marcos, E., Fadel, E., Sanchez, O., Humbert, M., Dartevelle, P., Simonneau, G., et al. 2004. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ. Res. 94(9): 1263-1270. doi:10.1161/01.RES.0000126847.27660.69. PMID:15059929.
32. Papaioannou, A.I., Zakynthinos, E., Kostikas, K., Kiropoulos, T., Koutsokera, A., Ziogas, A., et al. 2009. Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm. Med. 9(1): 18. doi:10.1186/1471-2466-9-18. PMID:19426547.
33. Partovian, C., Adnot, S., Eddahibi, S., Teiger, E., Levame, M., Dreyfus, P., et al. 1998. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am. J. Physiol. 275(6): H1948-H1956. PMID:9843792.
34. Peng, Y.J., Yuan, G., Ramakrishnan, D., Sharma, S.D., Bosch-Marce, M., Kumar, G.K., et al. 2006. Heterozygous HIF-1a deficiencyimpairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J. Physiol. 577(2): 705-716. doi:10.1113/jphysiol.2006.114033. PMID:16973705.
35. Perez-Vizcaino, F., Cogolludo, A., and Moreno, L. 2010. Reactive oxygen species signaling in pulmonary vascular smooth muscle. Respir. Physiol. Neurobiol. 174(3): 212-220. doi:10.1016/j.resp.2010.08.009. PMID:20797450.
36. Pfeifer, M., Blumberg, F.C., Wolf, K., Sandner, P., Elsner, D., Riegger, G.A., and Kurtz, A. 1998. Vascular remodeling and growth factor gene expression in the rat lung during hypoxia. Respir. Physiol. 111(2): 201-212. doi:10.1016/S0034-5687(97)00102-3. PMID:9574871.
37. Rosenkranz, S. 2008. Neue Konzepte in der Pathogenese derpulmonal arteriellen Hypertonie [Novel concepts in the pathobiology of pulmonary arterial hypertension]. Dtsch. Med.Wochenschr. 133(Suppl. 6): S167-S169. doi:10.1055/s-0028-1091229. PMID:18814087.
38. Shin, J.H., Shim, J.W., Kim, D.S., and Shim, J.Y. 2009. TGF-b effects on airway smooth muscle cell proliferation, VEGF release and signal transduction pathways. Respirology, 14(3): 347-353.doi:10.1111/j.1440-1843.2008.01469.x. PMID:19192227.
39. Yu, A.Y., Shimoda, L.A., Iyer, N.V., Huso, D.L., Sun, X., McWilliams, R., et al. 1999. Impaired physiological responses tochronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J. Clin. Invest. 103(5): 691-696. doi:10.1172/JCI5912. PMID:10074486.
40. Zhai, F.G., Zhang, X.H., and Wang, H.L. 2009. Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin. Exp. Pharmacol. Physiol. 36(8): 850-856.doi:10.1111/j.1440-1681.2009.05168.x. PMID:19298536.
41. Zhao, J.P., Zhou, Z.G., Hu, H.L., Guo, Z., Wang, T., Zhen, G.H., and Zhang, Z.X. 2007. The relationships among reactive oxygen species, hypoxia-inducible factor 1a and cell proliferation in rat pulmonary arterial smooth muscle cells under hypoxia. Sheng Li Xue Bao, 59(3): 319-324. PMID:17579787.